The highly selective CRF2 receptor antagonist K41498 binds to presynaptic CRF2 receptors in rat brain

British Journal of Pharmacology

Volumn 136, Issue 6, 2002, Pages 896-904

  Lawrence, Andrew J ^a   Krstew, E V ^a   Dautzenberg, F M ^a   Ruhmann A ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

K41498; Nucleus tractus solitarius

Indexed keywords

ADENYLATE CYCLASE; ANTALARMIN; ASTRESSIN; COMPLEMENTARY DNA; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CYCLIC AMP; IODINE 125; K 41498; PRESYNAPTIC RECEPTOR; RECEPTOR SUBTYPE; RECEPTOR SUBUNIT; SAUVAGINE; UNCLASSIFIED DRUG; UROCORTIN; (D PHE(11),HIS(12),NLE(17))SVG(11 40); (D-PHE(11),HIS(12),NLE(17))SVG(11-40); CARDIOVASCULAR AGENT; CRF RECEPTOR TYPE 2; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; BRAIN REGION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENZYME INHIBITION; GANGLIONECTOMY; GENETIC TRANSFECTION; HEART; HUMAN; HUMAN CELL; HYPOTENSION; KIDNEY CELL; MALE; NERVE ENDING; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SENSORY NERVE; VAGUS NERVE; AMINO ACID SEQUENCE; ANALYSIS OF VARIANCE; ANIMAL; AUTORADIOGRAPHY; BINDING SITE; BIOSYNTHESIS; BLOOD PRESSURE; BRAIN; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; HEART MUSCLE; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MOLECULAR GENETICS; NODOSE GANGLION; RADIOASSAY; WISTAR KYOTO RAT;

AMINO ACID SEQUENCE; ANALYSIS OF VARIANCE; ANIMAL; AUTORADIOGRAPHY; BINDING SITES; BINDING, COMPETITIVE; BLOOD PRESSURE; BRAIN; CARDIOVASCULAR AGENTS; CELL LINE; CYCLIC AMP; HUMAN; IN VITRO; INJECTIONS, INTRAVENOUS; MALE; MOLECULAR SEQUENCE DATA; MYOCARDIUM; NODOSE GANGLION; PEPTIDE FRAGMENTS; RADIOLIGAND ASSAY; RATS; RATS, INBRED WKY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RECEPTORS, PRESYNAPTIC; SUPPORT, NON-U.S. GOV'T; ANIMALS; HUMANS;

EID: 0036022633     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704783     Document Type: Article

References (45)

1. The role of corticotropin-releasing factor in depression and anxiety disorders
2. A receptors on rat vagal afferent neurons
3. 125I]α-bungarotoxin autoradiography
4. An oxidation resistant radioligand for corticotropin-releasing factor receptors
5. Presynaptic localization of opiate receptors in the vagal and accessory optic systems: An autoradiographic study
6. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress
7. Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: Implications for the treatment of CNS disorders
8. Comparison of central administration of corticotropin-releasing hormone and urocortin on food intake, conditioned taste aversion, and c-Fos expression
9. Urocortin expression in rat brain: Evidence against a pervasive relationship of urocortin-containing projections with targets bearing type 2 CRF receptors
10. Novel high-affinity photoactivatable antagonists of corticotropin-releasing factor (CRF) photo-affinity labeling studies on CRF receptor, type 1 (CRFR1)
11. Pharmacological and chemical properties of astressin, antisauvagine-30 and α-helCRF: Significance for behavioral experiments
12. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: Comparison with CRF1 receptor mRNA expression
13. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2
14. 2 receptors and the role of position 185 for receptor-ligand selectivity
15. Molecular biology of the CRH receptors-In the mood
16. Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: Evidence for evolutionary differences
17. 125I-antisauvagine-30: A novel and specific high-affinity radioligand for the characterization of corticotropin-releasing factor type 2 receptors
18. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety
19. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor
20. Regulation of corticotropin-releasing factor receptor type 2β messenger ribonucleic acid in the rat cardiovascular system by urocortin, glucocorticoids and cytokines
21. 7TM receptors: The splicing on the cake
22. Deletion of CRHr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2
23. L-glutamate as a neurotransmitter at baroreceptor afferents: Evidence from in vivo microdialysis
24. Neurochemical modulation of cardiovascular control in the nucleus tractus solitarius
25. 2 receptors on rat vagal afferent neurones
26. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor
27. CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues
28. Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain
29. 1 receptor: Design of small molecule inhibitors, receptor subtypes and clinical indications
30. Neuropeptide Y gene expression and receptor autoradiography in hypertensive and normotensive rat brain
31. Urocortin and corticotropin-releasing factor receptor expression in the human colonic mucosa
32. Isolation and pharmacological characterization of two functional splice variants of corticotropin-releasing factor type 2 receptor from Tupaia belangeri
33. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart
34. Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: Differential roles of CRF receptors 1 and 2
35. Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors
36. Comparison of hCRF and oCRF effects on cardiovascular responses after central, peripheral and in vitro application
37. 2 receptors: Membrane homogenate and autoradiographic studies
38. Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): Development of CRFR2beta-selective antisauvagine-30
39. Synthesis and characterization of a photoactivatable analogue of corticotropin releasing factor for specific receptor labeling
40. 2 receptors produces anxiolytic behavior in animal models of anxiety
41. Corticotropin-releasing factor (CRF) family of ligands and their receptors
42. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse
43. Fos induction in selective hypothalamic neuroendocrine and medullary nuclei by intravenous injection of urocortin and corticotropin-releasing factor in rats
44. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: Suppression of pituitary ACTH release and peripheral inflammation